Upgrade to SI Premium - Free Trial

PDL BioPharma (PDLI) Misses Q3 EPS by 19c

November 5, 2015 8:30 AM

PDL BioPharma (NASDAQ: PDLI) reported Q3 EPS of $0.42, $0.19 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $124.6 million versus the consensus estimate of $164.8 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

Categories

Earnings

Next Articles